A total of 95 participants was classified into 1 of 5 groups: healthy controls with no history of current invasive cancer (Group 1); newly diagnosed patients with intact prostate cancer (Group 2); patients who had no evidence of disease recurrence post local therapy (Group 3); patients with rising PSA after local therapy (Group 4); or patients with metastatic prostate cancer (Group 5). This evidence concerns the gene KLK3 and Familial prostate cancer.